膝の症候性軟骨または骨軟骨欠損を有する10〜17歳の患者におけるMACIの研究 (PEAK)
離断性骨軟骨炎または急性外傷
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
調査の概要
詳細な説明
This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).
After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.
All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.
Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.
Participants will be followed post-study treatment for 2 years (104 Weeks).
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Vericel Clinical Affairs
- 電話番号:978-347-2876
- メール:clinicalhotline@vcel.com
研究場所
-
-
California
-
Palo Alto、California、アメリカ、94304
- 募集
- Stanford University School of Medicine
-
コンタクト:
- Amishi Jobanputra
- 電話番号:650-498-4180
- メール:amishij@stanford.edu
-
主任研究者:
- Kevin Shea
-
Sacramento、California、アメリカ、95817
- 募集
- Shriners Hospital for Children Northern California
-
主任研究者:
- Brian Haus
-
コンタクト:
- Kory Bettencourt
- 電話番号:916-453-5030,
- メール:kbettencourt@shrinenet.org
-
Sacramento、California、アメリカ、95817
- 募集
- University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
-
主任研究者:
- Brian Haus
-
コンタクト:
- Julia Martin
- 電話番号:916-734-8175
- メール:jyhmartin@health.ucdavis.edu
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- 募集
- Ochsner Health System-Elmwood
-
コンタクト:
- Joseph Laurent
- 電話番号:504-842-0263
- メール:Joseph.laurent@ochsner.org
-
主任研究者:
- Brian Godshaw
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21224
- 募集
- Johns Hopkins Hospital
-
コンタクト:
- Rushyuan Jay Lee, MD
- 電話番号:443-997-2663
- メール:rlee74@jhmi.edu
-
コンタクト:
- Gabrielle Reichard
- 電話番号:410-502-3626
- メール:greicha1@jhmi.edu
-
主任研究者:
- Rushyuan Jay Lee
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- 募集
- University of Michigan Medsport Orthopaedic Surgery
-
コンタクト:
- Christopher Ray
- 電話番号:734-615-0934
- メール:raychri@med.umich.edu
-
主任研究者:
- Eileen Crawford
-
-
New York
-
The Bronx、New York、アメリカ、10467
- 完了
- Montefiore Medical Center/Albert Einstein College of Medicine
-
-
Ohio
-
Akron、Ohio、アメリカ、44308
- 募集
- Akron Children's Hospital
-
コンタクト:
- John Polousky, MD
- 電話番号:330-543-3500
- メール:JPolousky@akronchildrens.org
-
主任研究者:
- John Polousky
-
Columbus、Ohio、アメリカ、43202
- 募集
- The Ohio State University Jameson Crane Sports Medicine Institute
-
コンタクト:
- Jenna DeFranco
- 電話番号:614-293-2761
- メール:jenna.defranco@osumc.edu
-
主任研究者:
- Christopher Kaeding
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Penn Medicine University City
-
コンタクト:
- Dorothy Brill
- 電話番号:215-273-5062
- メール:dcbrill@upenn.edu
-
主任研究者:
- James Carey
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
-
コンタクト:
- Divya Talwar
- 電話番号:215-590-1527
- メール:talward@chop.edu
-
主任研究者:
- Theodore Ganley
-
-
Rhode Island
-
East Providence、Rhode Island、アメリカ、02914
- 募集
- University Orthopedics, Inc.
-
コンタクト:
- Cyndi Chrostek
- 電話番号:401-318-0529
- メール:cchrostek@brownhealth.org
-
主任研究者:
- Nicholas Lemme
-
-
Texas
-
Houston、Texas、アメリカ、77094
- 完了
- Texas' Children Hospital
-
Plano、Texas、アメリカ、75024
- 完了
- Children's Medical Center Plano
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53201
- 募集
- Children's Hospital of Wisconsin
-
コンタクト:
- John Erickson, DO
- 電話番号:414-337-7325
- メール:JErickson2@childrenswi.org
-
主任研究者:
- John Erickson
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Age 10 to 17 years at the time of planned randomization
-
Symptomatic cartilage or osteochondral defects
-
One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
- Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
-
At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
-
Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
-
Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
-
Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.
-
Written informed consent
Exclusion Criteria:
-
Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
-
Previous investigational drug or device use within 3 months prior to Screening
-
Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
-
Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
-
ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
-
Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
-
Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
-
Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
-
Known history of septic arthritis in the index knee joint
-
Current malignancy or treatment for malignancy within the past 5 years
-
Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
-
Females who are pregnant or lactating
-
Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:
- Any condition that has potential for negatively impacting intra or postoperative course
- Conditions that limit compliance with rehabilitation program
- Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
- Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
- Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:MACI
autologous cultured chondrocytes on porcine collagen membrane |
autologous cultured chondrocytes on porcine collagen membrane |
|
他の:microfracture
surgical procedure |
Arthroscopic microfracture treatment |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
時間枠:Baseline and Week 104
|
A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in KOOS-Child subscores
時間枠:Baseline and Week 104
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
|
Change from Baseline in KOOS-Child subscores
時間枠:Baseline and Week 52
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 52
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment Emergent Adverse Events
時間枠:Week 104
|
A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. |
Week 104
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd、Vericel Corporation
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。